News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Compass Pathways Releases Promising Findings From Phase 2 Clinical Trial of COMP360 Psilocybin With Antidepressants in Neuropsychopharmacology, a Nature Journal
Monday, July 17, 2023COMPASS Pathways plc Nasdaq CMPS has made an announcement regarding the publication of favorable data from an openlabel phase clinical trial in the esteemed journal Neuropsychopharmacology
Camurus Announces Phase 3 Trial Findings Supporting the Long-term Safety and Efficacy of Octreotide Sc Depot (CAM2029) in Acromegaly Patients
Monday, July 17, 2023Camurus a company listed on NASDAQ STO under the ticker symbol CAMX has recently shared interim topline data from a clinical trial called ACROINNOVA
Eucorvac-19 COVID-19 Vaccine by POP Biotechnologies and Eubiologics Achieves Target in Phase 3 Trial
Saturday, July 15, 2023Buffalobased biopharmaceutical startup POP Biotechnologies POP BIO has recently announced the interim results of a Phase clinical trial for EuCorVac a COVID vaccine candidate developed in partnership with South Korean company EuBiologics KOSDAQ
Positive Phase III Results Revealed for Roche's OCREVUS (Ocrelizumab): Twice-yearly, 10-minute Subcutaneous Injections in Multiple Sclerosis Patients
Friday, July 14, 2023Roche a pharmaceutical company has announced positive results from a recent clinical trial known as OCARINA II The trial investigated the use of OCREVUS ocrelizumab as a subcutaneous injection for the treatment of multiple sclerosis MS
Grifols Successfully Enrolls Participants in Phase 3 Study Evaluating Two Dose Regimens of Prolastin®-c for Emphysema Caused by Alpha-1-antitrypsin Deficiency
Friday, July 14, 2023Grifols a major producer of plasmaderived medications has announced that it has successfully enrolled patients in its phase clinical trial called SPARTA Study of ProlAstinc Randomized Therapy with Alpha augmentation NCT
Roche and KSQ Therapeutics Reach Global License Agreement for KSQ-4279, an Advanced USP1 Inhibitor for Cancer Therapy
Friday, July 14, 2023The molecule is currently in Phase clinical trials for solid tumors and has shown promising potential based on preclinical data Under the agreement Roche will take over the development of KSQ allowing KSQ to focus on advancing its immunotherapy prog...
Kamada and Kedrion Agree to Extend U.S. Distribution Agreement for KEDRAB® by Two Years
Thursday, July 13, 2023Kamada Ltd NASDAQ KMDA TASE KMDATA announced today that Kedrion has exercised its option to extend the distribution agreement with Kamada in the United States for KEDRAB Rabies Immune Globulin Human
George Medicines Concludes Recruitment for Initial Phase III Trial Assessing Innovative Single-pill Triple Combination Candidate GMRx2 in Hypertension
Thursday, July 13, 2023George Medicines a company specializing in latestage drug development and focused on revolutionizing the management of cardiometabolic disease has announced the successful completion of patient enrollment in its Phase III activecontrolled trial
Enterome Initiates Phase 2 Trial for EO2040 Immunotherapy in Colorectal Cancer, Focusing on Minimal Residual Disease Identified by ctDNA
Wednesday, July 12, 2023Enterome a clinicalstage company has initiated a Phase clinical trial called CLAUDE at The University of Texas MD Anderson Cancer Center to evaluate their novel immunotherapy candidate EO in patients with colorectal cancer CRC
Initiation of First Patient Dosing in Phase 1/2 Clinical Trial Investigating SAR'514/IPH6401 for Relapsed/Refractory Multiple Myeloma
Wednesday, July 12, 2023Innate Pharma SA Euronext Paris IPH Nasdaq IPHA has made an announcement regarding the initiation of a Phase clinical trial sponsored by Sanofi NCT This trial aims to assess the safety pharmacokinetics and preliminary efficacy of SAR IPH in patient...
